Amicus Therapeutics

February 5, 2012

Developments for Parkinson’s Disease Ignite Investor Enthusiasm

November 15, 2009 By MD Becker Partners Leave a Comment

948077-small

In our August 2009 article titled “Treating Parkinson’s Disease: Investment Opportunities and Challenges,” we reviewed some of the historical challenges associated with developing treatments for Parkinson’s disease [PD] and cited reasons for optimism going forward in addition to highlighting several promising companies making progress. Since that time, many of the companies we featured have reported [...]

Filed Under: Articles Tagged With: afegostat tartrate, Amicus Therapeutics, BioSante Pharmaceuticals, BPAX, CERE-120, Ceregene, Cogane, FOLD. Plicera, Gaucher's disease, glucocerebrosidase, Impax Laboratories, IPX066, IPXL, levodopa, Michael J. Fox Foundation, neeurotrophic factors, Neurologix, NLX-P101, NP201, NRGX, NuPathe, Oxford BioMedica, Parkinson's disease, Phytopharm, ProSavin, Shire plc, SHPGY, SRDX, SurModics

Treating Parkinson’s Disease: Investment Opportunities and Challenges

August 2, 2009 By MD Becker Partners 6 Comments

Parkinson’s disease [PD] is one of the most common of the neurogenerative diseases affecting 1 in 100 people over the age of 60. Approximately 1.5 million Americans currently suffer from the disease and it is estimated that 60,000 Americans are newly diagnosed each year. PD is both a chronic and progressive disease. While the precise [...]

Filed Under: Articles Tagged With: AAV, Addex Pharmaceuticals, adeno-associated virus, Amgen, AMGN, Amicus Therapeutics, Amsterdam Molecular Therapeutics, AVGN, Avigen, BDNF, CERE-120, Ceregene, CNS Protein Therapeutics, deep brain stimulation, DEPO, Depomed, dopamine, dopaminergic neurons, FOLD, GDNF, gene therapy, GENZ, Genzyme Corporation, glutamic acid decarboxylase, Impax Pharmaceuticals, Inc., IPX066, IPXL, L-dopa, LentiVector, levodopa, MANF, MDT, Medtronic, mesencephalic astrocyte-derived neurotrophic factor, Neurogen Corporation, Neurologix, neurotrophic factors, neurturin, NLX-P101, NRGN, NRGX, Oxford BioMedica, Parkinson's disease, PRAN, Prana Biotechnology, ProSavin, SynchoMed, Synergen, Unified Parkinson’s Disease Rating Scale

Genzyme’s Manufacturing Disruption Highlights Investment Opportunities in Lysosomal Storage Disorders

July 20, 2009 By MD Becker Partners 1 Comment

DNA abstract

Proteins are essential components of the human body. They perform specific biological functions within a cell and each type of protein has a unique function. For example, enzymes are proteins that help biochemical reactions to occur within the body. But before they can carry out these important functions, proteins must assemble into precise three-dimensional shapes [...]

Filed Under: Articles Tagged With: Amicus Therapeutics, Amigal, arimoclomol, biotech, biotechnology, Cerezyme, CYTR, CytRx Corporation, enzyme replacement therapy, Fabrazyme, Fabry, FOLD, Gaucher, GENZ, Genzyme Corporation, lysosomal storage disorders, Orphan Drug Act, Plicera, PLX, Pompe, prGCD, Protalix Biotherapeutics, Shire plc, SHPGY, velaglucerase alfa

Chink in the Biotechnology Armor

February 28, 2009 By MD Becker Partners 2 Comments

knight

Last week, the NASDAQ Biotech Index (NBI) declined more than 10 percent compared to an approximate 4.5 percent decline for the S&P 500. Since the NBI has been outperforming the broader market since mid-2008, this week’s relative underperformance came as quite a shock to many investors. Trying to explain the decline, most industry pundits pointed [...]

Filed Under: Articles Tagged With: Amicus Therapeutics, Ampligen, AT2220, biotech, biotechnology, FOLD, healthcare reform, HEB, Hemispherx Biopharma, La Jolla Pharmaceutical, LJPC, MAP Pharmaceuticals, MAPP, National Cancer Institute, Riquent, SNTA, Spectrum Pharmaceuticals, SPPI, Synta Pharmaceuticals, Zevalin